Corbus Pharmaceuticals Holdings, Inc. (CRBP)
7.14
-0.31
(-4.16%)
USD |
NASDAQ |
Sep 25, 16:00
7.16
+0.02
(+0.28%)
After-Hours: 19:59
Corbus Pharmaceuticals Holdings Enterprise Value : 19.64M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 19.64M |
| September 24, 2026 | 25.43M |
| September 23, 2026 | 30.84M |
| September 22, 2026 | 33.36M |
| September 21, 2026 | 29.16M |
| September 18, 2026 | 25.99M |
| September 17, 2026 | 21.88M |
| September 16, 2026 | 21.88M |
| September 15, 2026 | 15.53M |
| September 14, 2026 | 37.19M |
| September 11, 2026 | 37.94M |
| September 10, 2026 | 40.18M |
| September 09, 2026 | 51.75M |
| September 08, 2026 | 84.15M |
| September 04, 2026 | 93.20M |
| September 03, 2026 | 100.30M |
| September 02, 2026 | 100.67M |
| September 01, 2026 | 96.94M |
| August 31, 2026 | 90.03M |
| August 28, 2026 | 90.03M |
| August 27, 2026 | 94.14M |
| August 26, 2026 | 97.31M |
| August 25, 2026 | 97.50M |
| August 24, 2026 | 85.92M |
| August 21, 2026 | 80.13M |
| Date | Value |
|---|---|
| August 20, 2026 | 70.05M |
| August 19, 2026 | 72.85M |
| August 18, 2026 | 74.53M |
| August 17, 2026 | 82.19M |
| August 14, 2026 | 74.72M |
| August 13, 2026 | 74.53M |
| August 12, 2026 | 68.56M |
| August 11, 2026 | 63.89M |
| August 10, 2026 | 62.96M |
| August 07, 2026 | 76.21M |
| August 06, 2026 | 68.18M |
| August 05, 2026 | 65.01M |
| August 04, 2026 | 61.84M |
| August 03, 2026 | 52.87M |
| July 31, 2026 | 53.81M |
| July 30, 2026 | 55.30M |
| July 29, 2026 | 52.87M |
| July 28, 2026 | 55.95M |
| July 27, 2026 | 55.86M |
| July 24, 2026 | 57.54M |
| July 23, 2026 | 60.34M |
| July 22, 2026 | 51.38M |
| July 21, 2026 | 53.99M |
| July 20, 2026 | 52.31M |
| July 17, 2026 | 54.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.677B |
| Alnylam Pharmaceuticals, Inc. | 33.91B |
| Anika Therapeutics, Inc. | 259.45M |
| Savara, Inc. | 884.37M |
| Vericel Corp. | 1.964B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.04M |
| Total Expenses (Quarterly) | 35.04M |
| EPS Diluted (Quarterly) | -1.805 |
| Earnings Yield | -86.51% |
| Normalized Earnings Yield | -86.51 |